Company / Revenue
Regeneron Pharmaceuticals Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$14.3B
FY2025
5-year range
$6.6B / $14.3B
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
#11 of 155
Health Care
What the data says
Among 155 Health Care companies, Regeneron Pharmaceuticals is in the top 7% for revenue. Revenue has increased for 5 consecutive years, from $5.1B in FY2020 to $14.3B in FY2025.
Based on SEC 10-K filings.
$14.3B in FY2025 with a 5-year CAGR of +22.8%. Top quartile in the Health Care sector.
Improved from $13.1B to $14.3B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +19.1%
- 5-Year CAGR
- +22.8%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 155This company $14.3B Sector average $4.5B
▼
+220.8% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's revenue has grown for 5 consecutive years.
- 5-year CAGR of +22.8%, indicating consistent growth.
- In FY2025, revenue increased 1.0% year-over-year.
- Ranks #11 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.3B | +1.0% |
| FY2024 | $14.2B | +8.3% |
| FY2023 | $13.1B | +54.4% |
| FY2022 | $8.5B | +29.6% |
| FY2021 | $6.6B | +27.4% |
| FY2020 | $5.1B | -21.5% |
| FY2019 | $6.6B | +27.4% |
| FY2018 | $5.1B | +290.1% |
| FY2017 | $1.3B | -72.9% |
| FY2016 | $4.9B | +18.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026